Clinical trial · Observational
Low-grade Gliomas in Argentina: Incidence, Survival, and Therapeutic Strategies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Low-grade gliomas (LGG) are slow-growing primary brain tumors (WHO grades I-II), and their incidence, survival, and treatment patterns in middle-income settings such as Argentina remain poorly characterized. This retrospective, multicenter study comprises two complementary cohorts: 1. Cohort 1: The "captive" population covered under the Hospital Italiano de Buenos Aires Health Plan (January 2011-December 2023) to estimate LGG incidence density. 2. Cohort 2: Histologically confirmed LGG patients treated at the major referral centers to describe overall survival (OS) and disease-free survival (DFS) at 1 and 5 years. Demographic, clinical, pathological, and treatment data will be collected in a centralized REDCap database. The primary objective is to describe LGG incidence in Argentina and estimate survival using Kaplan-Meier curves. The secondary objectives include characterizing therapeutic strategies, molecular mutations, and prognostic factors through Cox regression analysis. This registry will fill a critical gap in LGG epidemiology in middle-income countries and generate hypotheses for future research.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Low-grade Glioma | Low Grade Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1: Incidence cohort
- description
- Affiliates of the Hospital Italiano Health Plan from January 2011 to December 2023 used to estimate the incidence density of low-grade gliomas.
- label
- Cohort 2: Survival cohort
- description
- Histologically confirmed low-grade glioma patients treated at participating centers, followed retrospectively for up to 5 years to assess overall and disease-free survival.
Primary outcomes (4)
- measure
- Describe the incidence density of LGG
- timeFrame
- January 2011 - December 2023
- description
- The incidence density will be estimated as the number of new cases of LGG divided by the person-time at risk (expressed in patient-years). The incidence stratified by age group, and sex, with corresponding 95% confidence intervals, will be described.
- measure
- Generate an Argentine population projection model
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Study population cohort 1 * Inclusion Criteria * Adult patients (≥18 years old) affiliated to the health plan of Hospital Italiano de Buenos Aires. * Documented clinical follow-up of at least 1 year during the study period. * Exclusion Criteria * Patients not affiliated to the health plan of the Hospital Italiano de Buenos Aires. Study population cohort 2 * Inclusion Criteria * Adult patients (≥18 years) with histopathologically confirmed diagnosis of low-grade glioma (WHO grades I and II). * Exclusion Criteria * Incomplete or doubtful diagnosis based on histopathologic and molecular criteria.
References
Publications (0)
Data not yet available